

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : **Confirmation No. 1112**
Edwin SOUTHERN : Attorney Docket No. 2004_0200
Serial No. 10/772,467 : Group Art Unit 1631
Filed February 6, 2004 : Examiner Anna Skibinsky
ANALYZING POLYNUCLEOTIDE
SEQUENCES : **Mail Stop: PUBLICATION**

REQUEST FOR REPUBLICATION UNDER 37 CFR 1.221(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Request is made for publication of the above-identified application under 37 CFR 1.221.

The publication fee of \$300.00 is charged to Deposit Account No. 23-0975.

The processing fee of \$130.00 is charged to Deposit Account No. 23-0975.

Any additional fees are authorized to be charged to same Deposit Account No.

A copy of the application in compliance with the Office electronic filing system requirements is enclosed.

Publication is hereby respectfully requested.

Respectfully submitted,

Edwin SOUTHERN

By: Wachuck

Warren M. Cheek
Registration No. 33,367
Attorney for Applicant

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
January 13, 2009

ANALYZING POLYNUCLEOTIDE SEQUENCES

This application is a divisional application of S.N. 09/422,803 filed October 22, 1999, which is a divisional application of S.N. 08/925,676 filed September 9, 1997, which is a divisional of application S.N. 08/230,012 filed April 19, 1994, now U.S. Patent No. 5 700,637, which is a continuation of abandoned application S.N. 08/695,682 filed May 3, 1991, which is a continuation-in-part of abandoned application S.N. 07/573,317 filed September 28, 1990, which is a 371 of international application PCT/GB89/00460 filed May 2, 1989.

1. INTRODUCTION

Three methods dominate molecular analysis of nucleic acid sequences: gel electrophoresis of restriction fragments, molecular hybridisation, and the rapid DNA sequencing methods. These three methods have a very wide range of applications in biology, both in basic studies, and in the applied areas of the subject such as medicine and agriculture. Some idea of the scale on which the methods are now used is given by the rate of accumulation of DNA sequences, which is now well over one million base pairs a year. However, powerful as they are, they have their limitations. The restriction fragment and hybridisation methods give a coarse analysis of an extensive region, but are rapid; sequence analysis gives the ultimate resolution, but it is slow, analysing only a short stretch at a time. There is a need for methods which are faster than the present methods, and in particular for methods which cover a large amount of sequence in each analysis.

This invention provides a new approach which produces both a fingerprint and a partial or complete sequence in a single analysis, and may be used directly with complex DNAs and populations of RNA without the need for cloning.

In one aspect the invention provides apparatus for analysing a polynucleotide sequence, comprising a support and attached to a surface therof an array of the whole or a

- chosen part of a complete set of oligo nucleotides of chosen lengths, the different oligonucleotides occupying separate cells of the array and being capable of taking part in hybridisation reactions. For studying differences between polynucleotide sequences, the invention provides in another aspect apparatus comprising a support and attached to a surface
- 5 thereof an array of the whole or a chosen part of a complete set of oligonucleotides of chosen lengths comprising the polynucleotide sequences, the different oligonucleotides occupying separate cells of the array and being capable of taking part in hybridisation reactions.

In another aspect, the invention provides a method of analysing a polynucleotide sequence, by the use of a support to the surface of which is attached an array of the whole or

10 a chosen part of a complete set of oligo nucleotides of chosen lengths, the different oligonucleotides occupying separate cells of the array, which method comprises labelling the polynucleotide sequence or fragments thereof to form labelled material, applying the labelled material under hybridisation conditions to the array, and observing the location of the label on the surface associated with particular members of the set of oligonucleotides.

15 The idea of the invention is thus to provide a structured array of the whole or a chosen part of a complete set of oligonucleotides of one or several chosen lengths. The array, which may be laid out on a supporting film or glass plate, forms the target for a hybridisation reaction. The chosen conditions of hybridisation and the length of the oligonucleotides must at all events be sufficient for the available equipment to be able to discriminate between

20 exactly matched and mismatched oligonucleotides. In the hybridisation reaction, the array is explored by a labelled probe, which may comprise oligomers of the chosen length or longer polynucleotide sequences or fragments, and whose nature depends on the particular application. For example, the probe may comprise labelled sequences amplified from genomic DNA by the polymerase chain reaction, or a mRNA population, or a complete set of

25 oligonucleotides from a complex sequence such as an entire genome. The end result is a set

of filled cells corresponding to the oligonucleotides present in the analysed sequence, and a set of "empty" sites corresponding to the sequences which are absent in the analysed sequence. The pattern produces a fingerprint representing all of the sequence analysed. In addition, it is possible to assemble most or all of the sequence analysed if an oligonucleotide length is chosen such that most or all oligonucleotide sequences occur only once.

- The number, the length and the sequences of the oligonucleotides present in the array "lookup table" also depend on the application. The array may include all possible oligonucleotides of the chosen length, as would be required if there was no sequence information on the sequence to be analysed. In this case, the preferred length of
10 oligonucleotide used depends on the length of the sequence to be analysed, and is such that there is likely to be only one copy of any particular oligomer in the sequence to be analysed. Such arrays are large. If there is any information available on the sequence to be analysed, the array may be a selected subset. For the analysis of a sequence which is known, the size of the array is of the same order as length of the sequence, and for many applications, such as
15 the analysis of a gene for mutations, it can be quite small. These factors are discussed in detail in what follows.

2. OLIGONUCLEOTIDES AS SEQUENCE PROBES

Oligonucleotides form base paired duplexes with oligonucleotides which have the complementary base sequence. The stability of the duplex is dependent on the length of the
20 oligonucleotides and on base composition. Effects of base composition on duplex stability can be greatly reduced by the presence of high concentrations of quaternary or tertiary amines. However, there is a strong effect of mismatches in the oligonucleotides duplex on the thermal stability of the hybrid, and it is this which makes the technique of hybridisation with oligonucleotides such a powerful method for the analysis of mutations, and for the
25 selection of specific sequences for amplification by DNA polymerase chain reaction. The

position of the mismatch affects the degree of destabilisation. Mismatches in the centre of the duplex may cause a lowering of the T_m by 10°C compared with 1°C for a terminal mismatch. There is then a range of discriminating power depending on the position of mismatch, which has implications for the method described here. There are ways of
5 improving the discriminating power, for example by carrying out hybridisation close to the T_m of the duplex to reduce the rate of formation of mismatched duplexes, and by increasing the length of oligonucleotide beyond what is required for unique representation. A way of doing this systematically is discussed.

3. ANALYSIS OF A PREDETERMINED SEQUENCE

10 One of the most powerful uses of oligonucleotide probes has been in the detection of single base changes in human genes. The first example was the detection of the single base change in the betaglobin gene which leads to sickle cell disease. There is a need to extend this approach to genes in which there may be a number of different mutations leading to the same phenotype, for example the DMD gene and the HPRT gene, and to find an efficient way
15 of scanning the human genome for mutations in regions which have been shown by linkage analysis to contain a disease locus for example Huntington's disease and Cystic Fibrosis. Any known sequence can be presented completely as a set of overlapping oligonucleotides. The size of the set is $N s + 1 = N$, where N is the length of the sequence and s is the length of an oligomer. A gene of 1 kb for example, may be divided into an overlapping set of around
20 one thousand oligonucleotides of any chosen length. An array constructed with each of these oligonucleotides in a separate cell can be used as a multiple hybridisation probe to examine the homologous sequence in any context, a single-copy gene in the human genome or a messenger RNA among a mixed RNA population, for example. The length s may be chosen such that there is only a small probability that any oligomer in the sequence is represented
25 elsewhere in the sequence to be analysed. This can be estimated from the expression given in

the section discussing statistics below. For a less complete analysis it would be possible to reduce the size of the array e.g. by a factor of up to 5 by representing the sequence in a partly or non-overlapping set. The advantage of using a completely overlapping set is that it provides a more precise location of any sequence difference, as the mismatch will scan in § 5 consecutive oligonucleotides.

4. ANALYSIS OF UNDETERMINED SEQUENCE

The genomes of all free living organisms are larger than a million base pairs and none has yet been sequenced completely. Restriction site mapping reveals only a small part of the sequence, and can detect only a small portion of mutations when used to compare two 10 genomes. More efficient methods for analysing complex sequences are needed to bring the full power of molecular genetics to bear on the many biological problems for which there is no direct access to the gene or genes involved. In many case, the full sequence of the nucleic acids need not be determined; the important sequences are those which differ between two nucleic acids. To give three examples: the DNA sequences which are different between a 15 wild type organism and one which carries a mutant can lead the way to isolation of the relevant gene; similarly, the sequence differences between a cancer cell and its normal counterpart can reveal the cause of transformation; and the RNA sequences which differ between two cell types point to the functions which distinguish them. These problems can be opened to molecular analysis by a method which identifies sequence differences. Using the 20 approach outlined here, such differences can be revealed by hybridising the two nucleic acids, for example the genomic DNA and the two genotypes, or the mRNA populations of two cell types to an array of oligonucleotides which represent all possible sequences. Positions in the array which are occupied by one sequence but not by the other show differences in two sequences. This gives the sequence information needed to synthesise 25 probes which can then be used to isolate clones of the sequence involved.

4.1 ASSEMBLING THE SEQUENCE INFORMATION

Sequences can be reconstructed by examining the result of hybridisation to an array. Any oligonucleotide of length s from within a long sequence, overlaps with two others over a length $s-1$. Starting from each positive oligonucleotide, the array may be examined for the 5 four oligonucleotides to the left and the four to the right that can overlap with one base displacement. If only one of these four oligonucleotides is found to be positive to the right, then the overlap and the additional base to the right determine s bases in the unknown sequence. The process is repeated in both directions, seeking unique matches with other positive oligonucleotides in the array. Each unique match adds a base to the reconstructed 10 sequence.

4.2 SOME STATISTICS

Any sequence of length N can be broken down to a set of $\sim N$ overlapping sequences s base pairs in length. (For double stranded nucleic acids, the sequence complexity of a sequence of N base pairs is $2N$, because the two strands have different sequences, but for the 15 present purpose, this factor of two is not significant). For oligonucleotides of length s , there are 4^s different sequence combinations. How big should s be to ensure that most oligonucleotides will be represented only once in the sequence to be analysed, of complexity N ? For a random sequence the expected number of s -mers which will be present in more than one copy is

$$20 \quad \mu_{>1} = 4^s (1 - e^{-\lambda}) (1 + \lambda)$$

where

$$\lambda = (N - s + 1)/4^s$$

For practical reasons it is also useful to know how many sequences are related to any given s -mer by a single base change. Each position can be substituted by one of three bases, 25 there are therefore $3s$ sequences related to an individual s -mer by a single base change, and

the probability that any s-mer is a sequence of N bases is related to any other s-mer in that sequence allowing one substitution is $3s \times N/4^S$. The relative signals of matched and mismatched sequences will then depend on how good the hybridisation conditions are in distinguishing a perfect match from one which differ by a single base. (If 4^S is an order of magnitude greater than N, there should only be a few, $3s/10$, related to any oligonucleotide by one base change.) The indications are that the yield of hybrid from the mismatched sequence is a fraction of that formed by the perfect duplex.

For what follows, it is assumed that conditions can be found which allow oligonucleotides which have complements in the probe to be distinguished from those which
 10 do not.

4.3 ARRAY FORMAT, CONSTRUCTION AND SIZE

To form an idea of the scale of the arrays needed to analyse sequences of different complexity it is convenient to think of the array as a square matrix. All sequences of a given length can be represented just once in a matrix constructed by drawing four rows representing
 15 the four bases, followed by four similar columns. This produces 4×4 matrix in which each of the 16 squares represents one of the 16 doublets. Four similar matrices, but one quarter the size, are then drawn within each of the original squares. This produces a 16×16 matrix containing all 256 tetranucleotide sequences. Repeating this process produces a matrix of any chosen depth, s, with a number of cells equal to 4^S . As discussed above, the choice of s
 20 is of great importance, as it determines the complexity of the sequence representation. As discussed below, s also determines the size of the matrix constructed, which must be very big for complex genomes. Finally, the length of the oligonucleotides determines the hybridisation conditions and their discriminating power as hybridisation probes.

			Size of Matrix	Number of
25	s	4^S	Genomes	(pixel = 100 μm ; Sheets of Film

	8	65536	$4^8 \times 10^0$		
	9	262144			
	10	1.0×10^6	cosmid	100mm	1
-	11	4.2×10^6			
5	12	1.7×10^7			
	13	6.7×10^7	E.coli		
	14	2.6×10^8	yeast	1.6 m	9
	15	1.1×10^9			
	16	4.2×10^9			
10	17	1.7×10^{10}			
	18	6.7×10^{10}	human	25 m	2,500
	19	2.7×10^{11}			
	20	1.1×10^{12}		100m	

The table shows the expected scale of the arrays needed to perform the first analysis
 15 of a few genomes. The examples are chosen because they are genomes which have either been sequenced by conventional procedures - the cosmid scale -, are in the process of being sequenced - the E. coli scale -, or for which there has been considerable discussion of the magnitude of the problem - the human scale. The table shows that the expected scale of the matrix approach is only a small fraction of the conventional approach. This is readily seen in
 20 the area of X-ray film that would be consumed. It is also evident that the time taken for the analysis would be only a small fraction of that needed for gel methods. The "Genomes" column shows the length of random sequence which would fill about 5% of cells in the matrix. This has been determined to be the optimum condition for the first step in the sequencing strategy discussed below. At this size, a high proportion of the positive signals

would represent single occurrences of each oligomer, the conditions needed to compare two genomes for sequence differences.

5. REFINEMENT OF AN INCOMPLETE SEQUENCE

Reconstruction of a complex sequence produces a result in which the reconstructed
5 sequence is interrupted at any point where an oligomer that is repeated in the sequence occurs. Some repeats are present as components of long repeating structures which form part of the structural organisation of the DNA, dispersed and tandem repeats in human DNA for example. But when the length of oligonucleotide used in the matrix is smaller than that needed to give totally unique sequence representation, repeats occur by chance. Such repeats
10 are likely to be isolated. That is, the sequences surrounding the repeated oligomer are unrelated to each other. The gaps caused by these repeats can be removed by extending the sequence to longer oligomers. In principle, those sequences shown to be repeated by the first analysis, using an array representation of all possible oligomers, could be resynthesised with an extension at each end. For each repeated oligomer, there would be $4 \times 4 = 16$ oligomers in
15 the new matrix. The hybridisation analysis would now be repeated until the sequence was complete. In practice, because the results of a positive signal in the hybridisation may be ambiguous, it may be better to adopt a refinement of the first result by extending all sequences which did not give a clear negative result in the first analysis. An advantage of this approach is that extending the sequence brings mismatches which are close to the ends in
20 the shorter oligomer, closer to the centre in the extended oligomer, increasing the discriminatory power of duplex formation.

5.1 A HYPOTHETICAL ANALYSIS OF THE SEQUENCE OF BACTERIOPHAGE λ DNA

Lambda phage DNA is 48,502 base pairs long. Its sequence has been completely
25 determined, we have treated one strand of this as a test case in a computer simulation of the

analysis. The table shows that the appropriate size of oligomer to use for a sequence of this complexity is the 10-mer. With a matrix of 10-mers, the size of 1024 lines square. After "hybridisation" of the lambda 10-mers in the computer, 46,377 cells were positive, 1957 had double occurrences, 75 triple occurrences, and three quadruple occurrences. These 46,377
5 positive cells represented known sequences, determined from their position in the matrix. Each was extended by four x one base at the 3' end and four x one case at the 5', end to give $16 \times 46,377 = 742,032$ cells. This extended set reduced the number of double occurrences to 161, a further 16-fold extension brought the number down to 10, and one more provided a completely overlapped result. Of course, the same end result of a fully overlapped sequence
10 could be achieved starting with a 4^{16} matrix, but the matrix would be 4000 times bigger than the matrix needed to represent all 10-mers, and most of the sequence represented on it would be redundant.

5.2 LAYING DOWN THE MATRIX

The method described here envisages that the matrix will be produced by synthesising
15 oligonucleotides in the cells of an array by laying down the precursors for the four bases in a predetermined pattern, an example of which is described above. Automatic equipment for applying the precursors has yet to be developed, but there are obvious possibilities; it should not be difficult to adapt a pen plotter or other computer-controlled printing device to the purpose. The smaller the pixel size of the array the better, as complex genomes need very
20 large numbers of cells. However, there are limits to how small these can be made. 100 microns would be a fairly comfortable upper limit, but could probably not be achieved on paper for reasons of texture and diffusion. On a smooth impermeable surface, such as glass, it may be possible to achieve a resolution of around 10 microns, for example by using a laser typesetter to preform a solvent repellant grid, and building the oligonucleotides in the
25 exposed regions. One attractive possibility, which allows adaptation of present techniques of

oligonucleotide synthesis, is to sinter microporous glass in microscopic patches onto the surface of a glass plate. Laying down very large number of lines or dots could take a long time, if the printing mechanism were slow. However, a low cost ink-jet printer can print at speeds of about 10,000 spots per second. With this sort of speed, 10^8 spots could be printed
5 in about three hours.

5.3 OLIGONUCLEOTIDE SYNTHESIS

There are several methods of synthesising oligonucleotides. Most methods in current use attach the nucleotides to a solid support of controlled pore size glass (CPG) and are suitable for adaptation to synthesis on a glass surface. Although we know of no description
10 of the direct use of oligonucleotides as hybridisation probes while still attached to the matrix on which they were synthesised, there are reports of the use of oligonucleotides as hybridisation probes on solid supports to which they were attached after synthesis. PCT Application WO 85/01051 describes a method for synthesising oligonucleotides tethered to a CPG column. In an experiment performed by us, CPG was used as the support in an Applied Bio-systems
15 oligonucleotide synthesiser to synthesise a 13-mer complementary to the left hand cos site of phage lambda. The coupling steps were all close to theoretical yield. The first base was stably attached to the support medium through all the synthesis and deprotection steps by a covalent link.

5.4 ANALYSING SEVERAL SEQUENCES SIMULTANEOUSLY

20 The method of this invention can be used to analyse several polynucleotide sequences simultaneously. To achieve this, the oligonucleotides may be attached to the support in the form of (for example) horizontal stripes. A technique for doing this is described in Example 3 below. Each DNA sample to be analysed is labelled and applied to the surface carrying the oligonucleotides in the form of a stripe (e.g. vertical) orthogonal to the oligonucleotide stripes

of the array. Hybridisation is seen at the intersections between oligonucleotide stripes and stripes of test sequence where there is homology between them.

Where sequence variations are known, an advantage of using this technique is that many different mutations can be probed simultaneously by laying down stripes corresponding
5 to each allelic variant. With a density of one oligonucleotide per mm, and one "individual" per 5mm, it should be possible to analyse 2000 loci on a plate 100 mm square. Such a high density of information, where the oligonucleotides do identify specific alleles, is not available by other techniques.

6. PROBES, HYBRIDISATION AND DETECTION

10 The yield of oligonucleotides synthesised on microporous glass is about 30 µmol/g. A patch of this material 1 micron thick by 10 microns square would hold $\sim 3 \times 10^{-12}$ µmol equivalent to about 2 g of human DNA. The hybridisation reaction could therefore be carried out with a very large excess of the bound oligonucleotides over that in the probe. So it should be possible to design a system capable of distinguishing between hybridisation
15 involving single and multiple occurrences of the probe sequence, as yield will be proportional to concentration at all stages in the reaction.

The polynucleotide sequence to be analysed may be of DNA or RNA. To prepare the probe, the polynucleotide may be degraded to form fragments. Preferably it is degraded by a method which is as random as possible, to an average length around the chosen length s of
20 the oligonucleotides on the support, the oligomers of exact length s selected by electrophoresis on a sequencing gel. The probe is then labelled. For example, oligonucleotides of length s may be end labelled. If labelled with ^{32}P , the radioactive yield of any individual s-mer even from total human DNA could be more than 10^4 dpm/mg of total DNA. For detection, only a small fraction of this is needed in a patch 10-100 microns square.
25 This allows hybridisation conditions to be chosen to be close to the Tm of duplexes, which

decreases the yield of hybrid and decreases the rate of formation, but increases the discriminating power. Since the bound oligonucleotide is in excess, signal need not be a problem even working close to equilibrium.

Hybridisation conditions can be chosen to be those known to be suitable in standard procedures used to hybridise to filters, but establishing optimum conditions is important. In particular, temperature needs to be controlled closely, preferably to better than $\pm 0.5^{\circ}\text{C}$. Particularly when the chosen length of the oligonucleotide is small, the analysis needs to be able to distinguish between slight differences of rate and/or extent of hybridisation. The equipment may need to be programmed for differences in base composition between different oligonucleotides. In constructing the array, it may be preferable to partition this into sub-matrices with similar base compositions. This may make it easier to define the T_m which may differ slightly according to the base composition.

The choice of hybridisation solvent is significant. When 1M NaCl is used, G:C base pairs are more stable than A:T base pairs. Double stranded oligonucleotides with a high G+C content have a higher T_m than corresponding oligonucleotides with a high A+T content. This discrepancy can be compensated in various ways: the amount of oligonucleotide laid down on the surface of the support can be varied depending on its nucleotide composition; or the computer used to analyse the data can be programmed to compensate for variations in nucleotide composition. A preferred method, which can be used either instead of or in addition to those already mentioned, is to use a chaotropic hybridisation solvent, for example a quaternary or tertiary amine as mentioned above. Tetramethylammoniumchloride (TMACl) has proved particularly suitable, at concentrations in the range 2 M to 5.5 M. At TMACl concentrations around 3.5 M to 4 M, the T_m dependence on nucleotide composition is greatly reduced.

- The nature of the hybridisation salt used also has a major effect on the overall hybridisation yield. Thus, the use of TMACl at concentrations up to 5 M can increase the overall hybridisation yield by a factor of 30 or more (the exact figure depending to some extent on nucleotide composition) in comparison with hybridisation using 1M NaCl.
- 5 Manifestly, this has important implications; for example the amount of probe material that needs to be used to achieve a given signal can be much lower.

Autoradiography, especially with ^{32}P causes image degradation which may be a limiting factor determining resolution; the limit for silver halide films is around 25 microns. Obviously some direct detection system would be better. Fluorescent probes are envisaged;

10 given the high concentration of the target oligonucleotides, the low sensitivity of fluorescence may not be a problem.

We have considerable experience of scanning auto-radiographic images with a digitising scanner. Our present design is capable of resolution down to 25 microns, which could readily be extended down to less than present application, depending on the quality of

15 the hybridisation reaction, and how good it is at distinguishing absence of a sequence from the presence of one or more. Devices for measuring astronomical plates have an accuracy around 1 μ . Scan speeds are such that a matrix of several million cells can be scanned in a few minutes. Software for the analysis of the data is straight-forward, though the large data sets need a fast computer.

20 Experiments presented below demonstrate the feasibility of the claims.

Commercially available microscope slides (BDH Super Premium 76 x 26 x 1 mm) were used as supports. These were derivatised with a long aliphatic linker that can withstand the conditions used for the deprotection of the aromatic heterocyclic bases, i.e. 30% NH₃ at 55° for 10 hours. The linker, bearing a hydroxyl group which serves as a starting point for

25 the subsequent oligonucleotide, is synthesised in two steps. The slides are first treated with a

25% solution of 3-glycidoxypropyltriethoxysilane in xylene containing several drops of Hunig's base as a catalyst. The reaction is carried out in a staining jar, fitted with a drying tube, for 20 hours at 90°C. The slides are washed with MeOH, Et₂O and air dried. Then neat hexaethylene glycol and a trace amount of conc. sulphuric acid are added and the mixture
5 kept at 80° for 20 hours. The slides are washed with MeOH, Et₂O, air dried and stored desiccated at -20° until use. This preparative technique is described in British Patent Application 8822228.6 filed 21 September 1988.

The oligonucleotide synthesis cycle is performed as follows:

The coupling solution is made up fresh for each step by mixing 6 vol. of 0.5M
10 tetrazole in anhydrous acetonitrile with 5 vol. of a 0.2M solution of the required beta-cyanoethylphosphoramidite. Coupling time is three minutes. Oxidation with a 0.1M solution of I₂ in THF/pyridine/H₂O yields a stable phosphotriester bond. Detritylation of the 5' end with 3% trichloroacetic acid in dichloromethane allows further extension of the oligonucleotide chain. There was no capping step since the excess of phosphoramidites used
15 over reactive sites on the slide was large enough to drive the coupling to completion. After the synthesis is completed, the oligonucleotide is deprotected in 30% NH₃ for 10 hours at 55°. The chemicals used in the coupling step are moisture-sensitive, and this critical step must be performed under anhydrous conditions in a sealed container, as follows. The shape of the patch to be synthesised was cut out of a sheet of silicone rubber (76 x 26 x 0.5 mm)
20 which was sandwiched between a microscope slide, derivatised as described above, and a piece of teflon of the same size and thickness. To this was fitted a short piece of plastic tubing that allowed us to inject and withdraw the coupling solution by syringe and to flush the cavity with Argon. The whole assembly was held together by fold-back paper clips. After coupling the set-up was disassembled and the slide put through the subsequent

chemical reactions (oxidation with iodine, and detritylation by treatment with TCA) by dipping it into staining jars.

EXAMPLE 1.

As a first example we synthesised the sequences oligo-dT₁₀-oligo-dT₁₄ on a slide by 5 gradually decreasing the level of the coupling solution in steps 10 to 14. Thus the 10-mer was synthesised on the upper part of the slide, the 14-mer at the bottom and the 11, 12 and 13-mers were in between. We used 10 pmol oligo-dA₁₂, labelled at the 5' end with ³²P by the polynucleotide kinase reaction to a total activity of 1.5 million c.p.m., as a hybridisation probe. Hybridisation was carried out in a perspex (Plexiglas) container made to fit a 10 microscope slide, filled with 1.2 ml of 1M NaCl in TE, 0.1% SDS, for 5 minutes at 20°. After a short rinse in the same solution without oligonucleotide, we were able to detect more than 2000 c.p.s. with a radiation monitor. An autoradiograph showed that all the counts came from the area where the oligonucleotide had been synthesised, i.e. there was no non-specific binding to the glass or to the region that had been derivatised with the linker only. After 15 partial elution in 0.1 M NaCl differential binding to the target is detectable, i.e. less binding to the shorter than the longer oligo-dT. By gradually heating the slide in the wash solution we determined the T_m (mid-point of transition when 50% eluted) to be 33°. There were no counts detectable after incubation at 39°. The hybridisation and melting was repeated eight times with no diminution of the signal. The result is reproducible. We estimate that at least 20 5% of the input counts were taken up by the slide at each cycle.

EXAMPLE 2.

In order to determine whether we would be able to distinguish between matched and mismatched oligonucleotides we synthesised two sequences 3' CCC GCC GCT GGA (cosL) and 3' CCC GCC TCT GGA, which differ by one base at position 7. All bases 25 except the seventh were added in a rectangular patch. At the seventh base, half of the

rectangle was exposed in turn to add the two different bases, in two stripes. Hybridisation of cosR probe oligonucleotide (5' GGG CGG CGA CCT) (kinase labelled with ^{32}P to 1.1 million c.p.m., 0.1 M NaCl, TE, 0.1% SDS) was for 5 hours at 32°. The front of the slide showed 100 c.p.s. after rinsing. Autoradiography showed that annealing occurred only to the

5 part of the slide with the fully complementary oligonucleotide. No signal was detectable on the patch with the mismatched sequence.

EXAMPLE 3.

For a further study of the effects of mismatches or shorter sequences on hybridisation behaviour, we constructed two arrays: one (a) of 24 oligonucleotides and the other (b) of 72

10 oligonucleotides.

These arrays were set out as shown in Table 1(a) and 1(b). The masks used to lay down these arrays were different from those used in previous experiments. Lengths of silicone rubber tubing (1mm o.d.) were glued with silicone rubber cement to the surface of plain microscope slides, in the form of a "U". Clamping these masks against a derivatised

15 microscope slide produced a cavity into which the coupling solution was introduced through a syringe. In this way only the part of the slide within the cavity came into contact with the phosphoramidite solution. Except in the positions of the mismatched bases, the arrays listed in Table 1 were laid down using a mask which covered most of the width of the slide. Off-setting this mask by 3mm up or down the derivatised slide in subsequent coupling reactions

20 produced the oligonucleotides truncated at the 3' or 5' ends.

For the introduction of mismatches a mask was used which covered half (for array (a)) or one third (for array (b)) of the width of the first mask. The bases at positions six and seven were laid down in two or three longitudinal stripes. This led to the synthesis of oligonucleotides differing by one base on each half (array (a)) or third (array (b)) of the slide.

In other positions, the sequences differed from the longest sequence by the absence of bases at the ends.

In array (b), there were two columns of sequences between those shown in Table 1(b), in which the sixth and seventh bases were missing in all positions, because the slide was
5 masked in a stripe by the silicone rubber seal. Thus there were a total of 72 different sequences represented on the slide in 90 different positions.

The 19-mer 5' CTC CTG AGG AGA AGT CTG C was used for hybridisation (2 million cpm, 1.2 ml 0.1M NaCl in TE, 0.1% SDS, 20°).

The washing and elution steps were followed by autoradiography. The slide was kept
10 in the washing solution for 5 min at each elution step and then exposed (45 min, intensified). Elution temperatures were 23, 36, 42, 47, 55 and 60°C respectively.

As indicated in the table, the oligonucleotides showed different melting behaviour. Short oligonucleotides melted before longer ones, and at 55°C, only the perfectly matched 19-mer was stable, all other oligonucleotides had been eluted. Thus the method can
15 differentiate between a 18-mer and a 19-mer which differ only by the absence of one base at the end. Mismatches at the end of the oligonucleotides and at internal sites can all be melted under conditions where the perfect duplex remains.

Thus we are able to use very stringent hybridisation conditions that eliminate annealing to mismatch sequences or to oligonucleotides differing in length by as little as one
20 base. No other method using hybridisation of oligonucleotides bound to the solid supports is so sensitive to the effects of mismatching.

EXAMPLE 4.

To test the application of the invention to diagnosis of inherited diseases, we hybridised the array (a), which carries the oligonucleotide sequences specific for the wild
25 type and the sickle cell mutations of the β-globin gene, with a 110 base pair fragment of

DNA amplified from the β -globin gene by means of the polymerase chain reaction (PCR).

Total DNA from the blood of a normal individual (1 microgram) was amplified by PCR in the presence of appropriate primer oligonucleotides. The resulting 110 base pair fragment was purified by electrophoresis through an agarose gel. After elution, a small sample (ca. 10 picogram) was labelled by using α - 32 P-dCTP (50 microCurie) in a second PCR reaction.

This PCR contained only the upstream priming oligonucleotide. After 60 cycles of amplification with an extension time of 9 min. the product was removed from precursors by gel filtration. Gel electrophoresis of the radioactive product showed a major band corresponding in length to the 110 base fragment. One quarter of this product (100,000 c.p.m. in 0.9 M NaCl, TE, 0.1% SDS) was hybridised to the array (a). After 2 hours at 30° ca. 15000 c.p.m. had been taken up. The melting behaviour of the hybrids was followed as described for the 19-mer in example 3, and it was found that the melting behaviour was similar to that of the oligonucleotide. That is to say, the mismatches considerably reduced the melting temperature of the hybrids, and conditions were readily found such that the perfectly matched duplex remained whereas the mismatched duplexes had fully melted.

Thus the invention can be used to analyse long fragments of DNA as well oligonucleotides, and this example shows how it may be used to test nucleic acid sequences for mutations. In particular it shows how it may be applied to the diagnosis of genetic diseases.

20 EXAMPLE 5.

To test an automated system for laying down the precursors, the cosL oligonucleotide was synthesised with 11 of the 12 bases added in the way described above. For the addition of the seventh base, however, the slide was transferred into an Argon filled chamber containing a pen plotter. The pen of the plotter had been replaced by a component, fabricated from Nylon, which had the same shape and dimensions as the pen, but which carried a

polytetrafluoroethylene (PTFE) tube, through which chemicals could be delivered to the surface of the glass slide which lay on the bed of the plotter. A microcomputer was used to control the plotter and the syringe pump which delivered the chemicals. The pen, carrying the delivery tube from the syringe, was moved into position above the slide, the pen was lowered and the pump activated to lay down coupling solution. Filling the pen successively with G, T and A phosphoramidite solutions an array of twelve spots was laid down in three groups of four, with three different oligonucleotide sequences. After hybridisation to cosR, as described in Example 2, and autoradiography, signal was seen only over the four spots of perfectly matched oligonucleotides, where the dG had been added.

10 EXAMPLE 6.

This example demonstrates the technique of analysing several DNA sequences simultaneously. Using the technique described in Example 3, a slide was prepared bearing six parallel rows of oligonucleotides running along its length. These comprised duplicate hexadecamer sequences corresponding to antisense sequences of the β -globin wild-type (A),
15 sickle cell (S) and C mutations. :

Clinical samples of AC, AS and SS DNA were procured. Three different single-stranded probes of 110 nt length with approx. 70,000 c.p.m. in 100 μ l 1M NaCl, TE pH 7.5, 0.1% SDS, viz AC, AS, and SS DNA were prepared. Radiolabelled nucleotide was included in the standard PCR step yielding a double-stranded labelled fragment. It was made single-stranded with Bacteriophage λ exonuclease that allowed to selectively digest one strand bearing a 5' phosphate. This was made possible by phosphorylating the downstream primer with T4 Polynucleotide kinase and ('cold') ATP prior to PCR. These three probes were applied as three stripes orthogonal to the surface carrying the six oligonucleotide stripes. Incubation was at 30°C for 2 hours in a moist chamber. The slide was then rinsed at ambient
25 temperature, then 45°C for 5 minutes and exposed for 4 days with intensification. The

genotype of each clinical sample was readily determined from the autoradiographic signals at the points of intersection.

EXAMPLE 7

A plate was prepared whose surface carried an array of all 256 octapurines. That is to say, the array comprised 256 oligonucleotides each consisting of a different sequence of A and G nucleotides. This array was probed with a mixture comprising all 256 octapyrimidines, each end labelled by means of polynucleotide kinase and Y-³²P-ATP. Hybridisation was performed for 6 - 8 hours at 4°C.

In consecutive experiments the hybridisation solvent was changed through the series 1M NaCl (containing 10mM Tris.HCl pH 7.5, 1mM EDTA, 7% sarcosine) and 2M, 2.5M, 3M, 3.5M, 4M, 4.5M, 5M and 5.5M TMAC1 (all containing 50mM Tris.HCl pH 8.0, 2mM EDTA, SDS at less than 0.04 mg/ml). The plate was rinsed for 10 minutes at 4°C in the respective solvent to remove only loosely matched molecules, sealed in a plastic bag and exposed to a PhorborImager storage phosphor screen at 4°C overnight in the dark.

The following table quotes relative signal intensities, at a given salt concentration, of hybrids formed with oligonucleotides of varying a content. In this table, the first row refers to the oligonucleotide GGGGGGGG, and the last row to the oligonucleotide AAAAAAAA. It can be seen that the difference in response of these two oligonucleotides is marked in 1M NaCl, but much less marked in 3M or 4M TMAC1.

Relative Intensities at given Salt Concentration

Solvent	Number of A's		
	0	4	8
5 1M NaCl	100	30	20
2M TMACl	100	70	30
3M TMACl	70	100	40
4M TMACl	60	100	40

10 The following table indicates relative signal intensities obtained, with octamers containing 4A's and 4G's, at different hybridisation salt concentrations. It can be seen that the signal intensity is dramatically increased at higher concentrations of TMACl.

Relative Intensities at different Salt Concentrations

15	Solvent	Yield of hybrid
1M NaCl		100
2M TMACl		200
3M TMACl		700
20 4M TMACl		2000

In conclusion, we have demonstrated the following:

1. It is possible to synthesise oligonucleotides in good yield on a flat glass plate.

2. Multiple sequences can be synthesised on the sample in small spots, at high density, by a simple manual procedure, or automatically using a computer controlled device.
 3. Hybridisation to the oligonucleotides on the plate can be carried out by a very simple procedure. Hybridisation is efficient, and hybrids can be detected by a short autoradiographic exposure.
 4. Hybridisation is specific. There is no detectable signal on areas of the plate where there are no oligonucleotides. We have tested the effects of mismatched bases, and found that a single mismatched base at any position in 10 oligonucleotides ranging in length from 12-mer to 19-mer reduces the stability of the hybrid sufficiently that the signal can be reduced to a very low level, while retaining significant hybridisation to the perfectly matched hybrid.
 5. The oligonucleotides are stably bound to the glass and plates can be used for hybridisation repeatedly.
- 15 The invention thus provides a novel way of analysing nucleotide sequences, which should find a wide range of application. We list a number of potential applications below:
- Small arrays of oligonucleotides as fingerprinting and mapping tools.
- Analysis of known mutations including genetic diseases.
- Example 4 above shows how the invention may be used to analyse mutations. There 20 are many applications for such a method, including the detection of inherited diseases.
- Genomic fingerprinting.
- In the same way as mutations which lead to disease can be detected, the method could be used to detect point mutations in any stretch of DNA. Sequences are now available for a number of regions containing the base differences which lead to restriction fragment length 25 polymorphisms (RFLPs). An array of oligonucleotides representing such polymorphisms

could be made from pairs of oligonucleotides representing the two allelic restriction sites. Amplification of the sequence containing the RFLP, followed by hybridisation to the plate, would show which alleles were present in the test genome. The number of oligonucleotides that could be analysed in a single analysis could be quite large. Fifty pairs made from 5 selected alleles would be enough to give a fingerprint unique to an individual.

Linkage analysis.

Applying the method described in the last paragraph to a pedigree would pinpoint recombinations. Each pair of spots in the array would give the information that is seen in the track of the RFLP analysis, using gel electrophoresis and blotting, that is now routinely used 10 for linkage studies. It should be possible to analyse many alleles in a single analysis, by hybridisation to an array of allelic pairs of oligonucleotides, greatly simplifying the methods used to find linkage between a DNA polymorphism and phenotypic marker such as a disease gene.

The examples above could be carried out using the method we have developed and 15 confirmed by experiments.

Large arrays of oligonucleotides as sequence reading tools.

We have shown that oligonucleotides can be synthesised in small patches in precisely determined positions by one of two methods: by delivering the precursors through the pen of a pen-plotter, or by masking areas with silicone rubber. It is obvious how a pen plotter could 20 be adapted to synthesise large arrays with a different sequence in each position. For some applications the array should be a predetermined, limited set; for other applications, the array should comprise every sequence of a predetermined length. The masking method can be used for the latter by laying down the precursors in a mask which produces intersecting lines. There are many ways in which this can be done and we give one example for illustration:

25 1. The first four bases, A, C, G, T, are laid in four broad stripes on a square plate.

2. The second set is laid down in four stripes equal in width to the first, and orthogonal to them. The array is now composed of all sixteen dinucleotides.
3. The third and fourth layers are laid down in four sets of four stripes one quarter the width of the first stripes. Each set of four narrow stripes runs within one of the broader stripes. The array is now composed of all 256 tetranucleotides.
4. The process is repeated, each time laying down two layers with stripes which are one quarter the width of the previous two layers. Each layer added increases the length of the oligonucleotides by one base, and the number of different oligonucleotide sequences by a factor of four.

The dimensions of such arrays are determined by the width of the stripes. The narrowest stripe we have laid is 1mm, but this is clearly not the lowest limit.

There are useful applications for arrays in which part of the sequence is predetermined and part made up of all possible sequences. For example:

15 Characterising mRNA populations.

Most mRNAs in higher eukaryotes have the sequence AAUAAA close to the 3' end. The array used to analyse mRNAs would have this sequence all over the plate. To analyse a mRNA population it would be hybridised to an array composed of all sequences of the type $N_mAATAAA N_n$. For $m + n = 8$, which should be enough to give a unique oligonucleotide

20 address to most of the several thousand mRNAs that is estimated to be present in a source such as a mammalian cell, the array would be 256 elements square. The 256 x 256 elements would be laid on the AATAAA using the masking method described above. With stripes of around 1mm, the array would be ca. 256mm square.

This analysis would measure the complexity of the mRNA population and could be 25 used as a basis for comparing populations from different cell types. The advantage of this

approach is that the differences in the hybridisation pattern would provide the sequence of oligonucleotides that could be used as probes to isolate all the mRNAs that differed in the populations.

Sequence determination.

- 5 To extend the idea to determine unknown sequences, using an array composed of all possible oligonucleotides of a chosen length, requires larger arrays than we have synthesised to date. However, it is possible to scale down the size of spot and scale up the numbers to those required by extending the methods we have developed and tested on small arrays. Our experience shows that the method is much simpler in operation than the gel based methods.

TABLE I

For Examples 3 and 4 array (a) was set out as follows:

20	GAG GAC TCC TCT ACG	20	GAG GAC aCC TCT ACG
36	GAG GAC TCC TCT GAC G	20	GAC GAC aCC TCT GAC G
5	36 GAG GAC TCC TCT AGA CG	20	GAC GAC aCC TCT AGA CG
	47 GAG GAC TCC TCT CAG ACG	36	GAG GAC aCC TCT CAG ACG
	60 GAG GAC TCC TCT TCA GAC G	47	GAG GAC aCC TCT TCA GAC G
	56 .AG GAC TCC TCT TCA GAC G	42	.AG GAC aCC TCT TCA GAC G
	56 ..G GAC TCC TCT TCA GAC G	42	..G GAC aCC TCT TCA GAC G
10	47 ... GAC TCC TCT TCA GAC G	42	... GAC aCC TCT TCA GAC G
	42AC TCC TCT TCA GAC G	36AC aCC TCT TCA GAC G
	36C TCC TCT TCA GAC G	36C aCC TCT TCA GAC G
	36 TCC TCT TCA GAC G	36 aCC TCT TCA GAC G
	36CC TCT TCA GAC G	36CC TCT TCA GAC G
15			

For example 3 array (b) was set out as follows:

20	GAG GAT TC	20	GAG GAC TC	20	GAG GAC aC
20	GAG GAT TC	20	GAG GAC TCC	20	GAG GAC aCC
20	GAG GAT TCC T	20	GAG GAC TCC T	20	GAG GAC aCC T
20	20 GAG GAT TCC TC	20	GAG GAC TCC TC	20	GAG GAC aCC TC
20	20 GAG GAT TCC TCT	20	GAG GAC TCC TCT	20	GAG GAC aCC TCT
20	20 GAG GAT TCC TCT T	20	GAG GAC TCC TCT T	20	GAG GAC aCC TCT T
20	20 GAG GAT TCC TCT TC	20	GAG GAC TCC TCT TC	20	GAG GAC aCC TCT TC
20	20 GAG GAT TCC TCT TCA	20	GAG GAC TCC TCT TCA	20	GAG GAC aCC TCT TCA
25	32 GAG GAT TCC TCT TCA G	42	GAG GAC TCC TCT TCA G	20	GAG GAC aCC TCT TCA G
	32 GAG GAT TCC TCT TCA GA	47	GAG GAC TCC TCT TCA GA	32	GAG GAC aCC TCT TCA GA
	42 GAG GAT TCC TCT TCA GAC	52	GAG GAC TCC TCT TCA GAC	42	GAG GAC aCC TCT TCA GAC
	52 GAG GAT TCC TCT TCA GAC G	60	GAG GAC TCC TCT TCA GAC G	52	GAG GAC aCC TCT TCA GAC G
	42 .AG GAT TCC TCT TCA GAC G	52	.AG GAC TCC TCT TCA GAC G	42	.AG GAC aCC TCT TCA GAC G
30	42 ..G GAT TCC TCT TCA GAC G	52	..G GAC TCC TCT TCA GAC G	42	..G GAC aCC TCT TCA GAC G
	37 ... GAT TCC TCT TCA GAC G	47	... GAC TCC TCT TCA GAC G	37	... GAC aCC TCT TCA GAC G
	32At TCC TCT TCA GAC G	42AC TCC TCT TCA GAC G	32AC aCC TCT TCA GAC G
	32t TCC TCT TCA GAC G	42C TCC TCT TCA GAC G	32C aCC TCT TCA GAC G
	32TCC TCT TCA GAC G	32TCC TCT TCA GAC G	32TCC TCT TCA GAC G

Between the three columns of array (b) listed above, were two columns, in which bases 6 and 7 from the left were missing in every line. These sequences all melted at 20 or 32 degrees. (a,t) mismatch base (.) missing base.

CLAIMS

Claim 1. Apparatus for analysing a polynucleotide, the apparatus comprising: a support having an impermeable surface; porous material attached to the impermeable surface; and an array of oligonucleotides with predetermined sequences attached to the porous material, wherein the array comprises at least two defined cells, the sequence of the oligonucleotides of a first cell is different from the sequence of the oligonucleotides of a second cell, and the oligonucleotides are shorter than the polynucleotide.

Claim 2. Apparatus of claim 1, wherein the porous material is a microporous material.

Claim 3. Apparatus of claim 1, wherein the support is made of a silicon oxide.

Claim 4. Apparatus of claim 3, wherein the support is made of glass.

Claim 5. Apparatus of claim 1, comprising between 72 and 1.1×10^{12} cells.

Claim 6. Apparatus of claim 1, wherein each cell holds at least 3×10^{-12} mmol of oligonucleotide.

Claim 7. Apparatus of claim 1, wherein the oligonucleotides are covalently attached to the porous material.

Claim 8. Apparatus of claim 7, wherein the oligonucleotides are covalently attached by a terminal nucleotide.

Claim 9. Apparatus of claim 1, wherein the oligonucleotides are synthesized *in situ*.

Claim 10. Apparatus of claim 1, wherein the apparatus is manufactured using a computer-controlled device.

Claim 11. Apparatus of claim 10, wherein the computer-controlled device is a printing device.

Claim 12. Apparatus for analysing a polynucleotide, the apparatus comprising: a support having an impermeable surface; porous material attached to the impermeable surface; and an array of oligonucleotides with predetermined sequences attached to the porous material, wherein the array comprises at least two defined cells, the sequence of the oligonucleotides of a first cell is different from the sequence of the oligonucleotides of a second cell, and the oligonucleotides are shorter than the polynucleotide, wherein the oligonucleotides are covalently attached to the porous material.

Claim 13. Apparatus of claim 12, wherein the oligonucleotides are covalently attached by a terminal nucleotide.

ABSTRACT

An apparatus is provided for analysing a polynucleotide. The apparatus includes: a support having an impermeable surface; porous material attached to the impermeable surface; and an array of oligonucleotides with predetermined sequences attached to the porous material. The array includes at least two defined cells, the sequence of the oligonucleotides of a first cell being different from the sequence of the oligonucleotides of a second cell, and the oligonucleotides being shorter than the polynucleotide.

SEQUENCE LISTING

<110> SOUTHERN, EDWIN

<120> ANALYZING POLYNUCLEOTIDE SEQUENCES

<130> 2004-0200/WMC/01779

<140> 10/772,467

<141> 2004-02-06

<150> 09/422,803

<151> 1999-10-22

<150> 08/925,676

<151> 1997-09-09

<150> 08/230,012

<151> 1994-04-19

<150> 07/695,682

<151> 1991-05-03

<150> 07/753,317

<151> 1990-09-28

<150> PCT/GB89/00460

<151> 1989-05-02

<160> 76

<170> PatentIn Ver. 2.1

<210> 1

<211> 12

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 1

aggcgccgc cc

12

<210> 2

<211> 12

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 2

aggctccgc cc

12

<210> 3

<211> 12

<212> DNA

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 3
gggcggcgac ct

12

<210> 4
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 4
ctcctgagga gaagtctgc

19

<210> 5
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 5
gaggactcct ctacg

15

<210> 6
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 6
gaggactcct ctgacg

16

<210> 7
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
Oligonucleotide

<400> 7
gaggactcct ctagacg

17

<210> 8
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 8
gaggactcct ctcagacg

18

<210> 9
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 9
gaggactcct cttcagacg

19

<210> 10
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 10
aggactccct ttcagacg

18

<210> 11
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 11
ggactcctct tcagacg

17

<210> 12
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 12
gactcctctt cagacg

16

<210> 13
<211> 15
<212> DNA

<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 13
actcccttttc agacg 15

<210> 14
<211> 14
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 14
tcctcattca gacg 14

<210> 15
<211> 13
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 15
tcctttttag acg 13

<210> 16
<211> 12
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 16
ccttttcaga cg 12

<210> 17
<211> 15
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 17
gaggacacct ctacg 15

<210> 18
<211> 16

<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 18
gacgacacct ctgacg 16

<210> 19
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 19
gacgacacct ctagacg 17

<210> 20
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 20
gaggacacct ctcagacg 18

<210> 21
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 21
gaggacacct cttcagacg 19

<210> 22
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 22
aggacacacctc ttccagacg 18

<210> 23

<211> 17	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic Oligonucleotide	
<400> 23	
ggacacctct tcagacg	17
<210> 24	
<211> 16	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic Oligonucleotide	
<400> 24	
gacacaccttt cagacg	16
<210> 25	
<211> 15	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic Oligonucleotide	
<400> 25	
acacaccttca agacg	15
<210> 26	
<211> 14	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic Oligonucleotide	
<400> 26	
cacctttca gacg	14
<210> 27	
<211> 13	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: synthetic Oligonucleotide	
<400> 27	
acctttcag acg	13

<210> 28
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 28
cctcttcaga cg 12

<210> 29
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 29
gaggattcct 10

<210> 30
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 30
gaggattcct c 11

<210> 31
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 31
gaggattcct ct 12

<210> 32
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 32
gaggattcct ctt 13

<210> 33
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 33
gaggattcct cttc 14

<210> 34
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 34
gaggattcct cttca 15

<210> 35
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 35
gaggattcct cttag 16

<210> 36
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 36
gaggattcct cttaga 17

<210> 37
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 37
gaggattcct cttagac 18

<210> 38
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 38
gaggattcct cttcagacg 19

<210> 39
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 39
aggattccctc ttccagacg 18

<210> 40
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 40
ggatccctct tcagacg 17

<210> 41
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 41
gattccctctt cagacg 16

<210> 42
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 42

attcccttc agacg 15

<210> 43
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 43
ttcccttca gacg 14

<210> 44
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 44
tccttcag acg 13

<210> 45
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 45
gaggactcct 10

<210> 46
<211> 11
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 46
gaggactcct c 11

<210> 47
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 47
gaggactcct ct

12

<210> 48
<211> 13
<212> DNA
<213> Artificial sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 48
gaggactcct ctt

13

<210> 49
<211> 14
<212> DNA
<213> Artificial sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 49
gaggactcct ctcc

14

<210> 50
<211> 15
<212> DNA
<213> Artificial sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 50
gaggactcct ctcca

15

<210> 51
<211> 16
<212> DNA
<213> Artificial sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 51
gaggactcct cttag

16

<210> 52
<211> 17
<212> DNA
<213> Artificial sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

11

<400> 52
gaggactcct cttcaga 17

<210> 53
<211> 18
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 53
gaggactcct cttcagac 18

<210> 54
<211> 19
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 54
gaggactcct cttcagacg 19

<210> 55
<211> 18
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 55
aggactcctc ttcagacg 18

<210> 56
<211> 17
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 56
ggactcctct tcagacg 17

<210> 57
<211> 16
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic 12

Oligonucleotide

<400> 57
gactccctttt cagacg

<210> 58
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 58
actccctttc agacg

<210> 59
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 59
ctccctttca gacg

<210> 60
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 60
tcctcttcag acg

<210> 61
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 61
gaggacacctt

<210> 62
<211> 11
<212> DNA
<213> Artificial Sequence

<220>

16

15

14

13

10

<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 62
gaggacacct c

11

<210> 63
<211> 12
<212> DNA
<213> Artificial sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 63
gaggacacct ct

12

<210> 64
<211> 13
<212> DNA
<213> Artificial sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 64
gaggacacct ctt

13

<210> 65
<211> 14
<212> DNA
<213> Artificial sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 65
gaggacacct cttc

14

<210> 66
<211> 15
<212> DNA
<213> Artificial sequence

<220>
<223> Description of Artificial Sequence: Synthetic Oligonucleotide

<400> 66
gaggacacct ctca

15

<210> 67
<211> 16
<212> DNA
<213> Artificial sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 67
gaggacacct cttcag

16

<210> 68
<211> 17
<212> DNA
<213> Artificial sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 68
gaggacacct cttcaga

17

<210> 69
<211> 18
<212> DNA
<213> Artificial sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 69
gaggacacct cttcagac

18

<210> 70
<211> 19
<212> DNA
<213> Artificial sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 70
gaggacacct cttcagacg

19

<210> 71
<211> 18
<212> DNA
<213> Artificial sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 71
aggacacacctc ttcaagcg

18

<210> 72
<211> 17
<212> DNA
<213> Artificial sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 72
ggacacctct tcagacg 17

<210> 73
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 73
gacacctttt cagacg 16

<210> 74
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 74
acaccttttc agacg 15

<210> 75
<211> 14
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 75
cacctttca gagc 14

<210> 76
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Oligonucleotide

<400> 76
acctttcag acg 13